In the current study, we investigated the effectiveness of the three agents with bone anabolic properties approved by the FDA for the treatment of osteoporosis: teriparatide/parathyroid hormone 1-34 (PTH), abaloparatide/PTH-related peptide 1-34 (ABL), and romosozumab/anti-sclerostin antibody (Scl-Ab)], in restoring the weakened bone structure using a preclinical murine model of established T2-DM. This evidence concerns the gene PTH and diabetes mellitus.